Christopher M. Treleaven

Statistics

Publications

Citations

1.6K

H-Index

Active since

2005

Affiliations

SynZyme Technologies (United States)(Current)

Beth Israel Deaconess Medical Center

Harvard University

Nationwide Children's Hospital

Framingham State University

Christopher M. Treleaven is an author at SynZyme Technologies (United States) specializing in neuroscience, life sciences, and neurodegenerative diseases.

Publications per year

2005–2022

Publications

Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies

S. Pablo Sardi, Jennifer Clarke, Catherine Viel et al. · Proceedings of the National Academy of Sciences · 2013 · 247 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models

S. Pablo Sardi, Catherine Viel, Jennifer Clarke et al. · Proceedings of the National Academy of Sciences · 2017 · 200 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease

Lisa M. Stanek, S. Pablo Sardi, Bryan Mastis et al. · Human Gene Therapy · 2014 · 164 citations · Full text

Life Sciences, Molecular Biology, Neuroscience +17

Delivery of AAV-IGF-1 to the CNS Extends Survival in ALS Mice Through Modification of Aberrant Glial Cell Activity

James C. Dodge, Amanda M. Haidet, Wendy Yang et al. · Molecular Therapy · 2008 · 157 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis

James C. Dodge, Christopher M. Treleaven, Joshua Pacheco et al. · Proceedings of the National Academy of Sciences · 2015 · 135 citations · Full text

Life Sciences, Neurology, Neuroscience +15

1–5 of 16